Member Info for Cliostock

It’s a non issue, using accounting practices properly.

Lol, I hope you were paid for that Elric! I was looking forward to reading TW’s write up, it was less write and more copy and paste!

You too Elric.

I think SA dropped a mega hint by mentioning the number of products in the portfolio of the potential acquisition. That must rule the potential firms down by quite a margin. I’ll be doing my own research on this over the New Year period and seeing what tallies up.

Elrico,

I can understand that, it makes sense.

And the 120k-ish that it has raised will not go to waste, I’m sure.

It applies to each individual though when considering their course of action, including me who bought in the market, so it’s definitely a contributing factor to less money raised in the REX than if it was at a genuine discount at the time the investors decision is being made. Of course you have a point that once too many people do this the price rises. However it was a non issue despite one day someone buying 163000 shares in one trade.

To add a third point to you list Aquae, what’s the point of PI’s buying new shares which dilute them when they can buy on the open market for the same or very slightly less over the last few days and support the share price.

Very good Elric, well done

Elrico,

Fantastic to hear you have spoken to Stuart and sorry to hear you had covid. I had my first experience with it last month, and it was much worse than I imagined it would be and am only just over the after effects. At one point I felt so bad I checked my will to make sure everything was in order!

This may be in contraction to your arrangements with Stuart so if that’s the case ignore me - but if the only reason you don’t want to post the interview is because of your croaky voice, I think I speak for us all in saying we can forgive how you look or sound of it means we can hear the full lot. I think the interviews where we can hear the conversations are always a lot more useful than the written Q&A ones. There is always as much to be taken from the way SA reacts to a question or the tone of his answer which is totally removed in writing.

Food for thought and get well soon, all the best.

Re the offer Ody, it remains to be seen how many people buy at 16p, you might end up bring right, it might be fully subscribed.

Re the bright study, the results were great, I don’t think that’s even debatable.

I’d say volatile would be a better word than risky Oleric. Now the placing is completed with the REX funds to come and the price at only 16p, i don’t think it’s risky. There will just be volatility depending on timings of progression updates. It will become risky in 12 /18 months if nothing has been achieved, I guess it depends if you think it will come to that. I’m not pleased with progression this year, but I’m hopeful 2023 will be much more fruitful.

Hopefully Elric can get an interview in his usual style soon. The Proactive ones are a bit soft to say the least, but any interview is better than none and it’s good Stuart hasn’t gone in to hiding as so many CEO’s seem to do when investors are piling the pressure on for answers.

Elrico, should investors have to decipher clues or put puzzles together from an RNS? If it’s there they should say it, if it’s not said it’s not there. I think most people here have had enough of supposed hidden meanings. If it’s not said explicitly then there is a reason it’s not said, and that reason is not to the advantage of the shareholders. I do believe the company still has plenty of good things going for it, but if a company with a waining SP doesn’t put a good point in a general update then I think it’s fair to say it’s probably not there.

I have read the RNS through a few times and had chance to process the releases. To save writing an essay, I can say that Aquae’s post from 20:01 sums my thoughts up perfectly. I’m very disappointed and I feel like the CEO as both underperformed and pulled the wool over our eyes. Some things don’t quite add up. Totally agree that Danielle Bekker needs to be immediately relieved of her duty, whatever that was supposed to be. I appreciate the long RNS which was obviously an increased effort to fully inform us. There are some positives here and there, such as the acquisition. But for me the company has been badly managed recently. Like many here I’m strongly weighted towards this share and now feeling exposed to my paper losses. I do take responsibility for my position, but the real cause is the difference between what Stuart implied he was going to achieve on many occasions and the reality of what is being produced. Very disappointed, time to put these shares in the bottom drawer for a while and see if he manages to provide me with at least the value invested at some point, or if the company is as much as a let down as it seems to be right now.

Well that was an interesting read. Talk about the chink in Stuart’s armour back in March. He’s going to look like an Alabama road sign after this. Put the snorkel on boys, we’re going down tomorrow!!

I had some real fun there trying to work out what BBM meant. I had all sorts of hilarious phrases in mind before eventually realising it stands for Bulletin Board Moron!!

I second what you guys are saying and also blame the waning SP directly on the board. When the 1.2m was missed, we were promised the team would be “breaking their backs” to make it right. One update RNS in 9 months is hardly breaking a sweat, never mind a back. The update part should have come out before the results if the CFO was taking his time on the accounts. Really want to believe Stuart’s positive words when he is interviewed, but how much more frustration does he want to put us through before he delivers something relating to making money rather than spending it.

A lower bar than is standard practice for use on what though Oleric? This is a food supplement, not a medical device. If we ran the studies and obtained the proof you suggest we should have, the product would no longer be a food supplement.

Let’s look at CBD as an example, which I would suggest is one of the most common food supplements around at the moment. See this extract from Dr. Peter Grinspoon of Harvard Medical School: “Without sufficient high-quality evidence in human studies, we can’t pinpoint effective doses, and because CBD currently is typically available as an unregulated supplement, it’s hard to know exactly what you are getting.”

Fact is, you don’t NEED to go to the lengths you are suggesting to release a food supplement to help with a condition, and if most similar products don’t, I think that shows the bar of standard practice is set lower than you are suggesting.

Regarding the acne product, there is nothing material I can say to alleviate your concerns. What I would say though, is that of concerns I personally have with this company, their ability to produce an effective product to help a skin condition is certainly not one of them. Cath says it will work, Stuart says he can put it in gum. That’s all I need. Now whether they will order £400,000 worth and then try and sell it at car boot sales is more of a valid concern. Joke!

Sneering at Elric is pointless unless you care to admit you have blindly followed him without doing your own research. Now if you would have said where has Stuart been this year, I’d possibly support the sentiment.

If you were right Oleric, I would genuinely support your argument (in the discussion sense), but what Toyin is saying is accurate. We have the bright study which shows a great level of efficacy, and we know the reasons for why it was not done clinically. Dr Jonathan Sheffield is working with the company on a medically measured study, but we don’t need that to prove it works - as Toyin says, we do know it works 100%. This doesn’t allow us to make claims but that was a decision made by the company.

Also just to add, one product in one pillar. Granted it’s the only one generating revenue but we should have a lot coming up soon to sit alongside AxisBiotix, quantify/quality as yet unknown!

“I am a man of great experience...I would say an expert in the science” is not a statement qualified by a long post trying to preach a very extreme standpoint. Chances are some of what you say will be correct, some will not be.

Please try a bit of balanced thinking now and again. It would certainly have helped you not to buy high, sell low, TWICE. (“I am a very experienced investor”)

Recognise that with SBTX, like all companies with such high potential returns, there are high risks and high volatility and that’s not for everyone, only those that are confident in their own constitution. There is a chance that Stuart is a poor operator who is also a great actor. He might bring in Croda revenue and an Axis deal in H1 and the SP might be 60p. Don’t act like you can be so sure which way it’s going to go just because you have lost money, it makes you sound so bitter.